How Psychedelic Biotech Is Reshaping Mental Health | Eric So - CEO, Helus Pharma

Psychedelic biotech offers new paradigms for mental health treatment by shifting from symptom management to root cause resolution through neuroplasticity and neural circuit restructuring. Rather than relying on traditional medication that requires daily administration, these novel psychedelic-derived therapies aim for durable effects with fewer doses, potentially reducing reliance on chronic pharmaceutical regimens and minimizing systemic side effects. Helus Pharma employs chemical modification techniques such as deuteration to optimize these compounds, enhancing blood-brain barrier permeability and extending therapeutic windows. By developing these treatments, companies are seeking to improve patient outcomes for major depressive disorder and treatment-resistant conditions through scalable, evidence-based approaches.